
|Videos|May 1, 2013
Patrick Gleason of Prime Therapeutics on Pharmacogenomic Testing
Patrick Gleason, PharmD, BCPS, FCCP, director of Health Outcomes at Prime Therapeutics, discusses the value of pharmacogenomic testing and the factors that influence whether a health plan or PBM will reimburse for the use of that test.
Advertisement
Patrick Gleason, PharmD, BCPS, FCCP, director of Health Outcomes at Prime Therapeutics, discusses the value of pharmacogenomic testing and the factors that influence whether a health plan or PBM will reimburse for the use of that test.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
New CKD Outcome Set Tells Pharmacists What to Measure
2
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
3
The PBM Reform Clock Is Running to 2028—Here's What Independent Pharmacies Should Do
4
GLP-1s and the HCM–Sleep Apnea–Obesity Connection
5


































































































